Ozempic or Mounjaro – which drug is more effective in the fight against obesity?

In recent years, Ozempic and Mounjaro have become hot names in the world of type 2 diabetes treatment and weight loss therapy. Although both drugs have similar applications, they differ in their mechanism of action, effectiveness and – crucially for many – price. Which one to choose? And why are they increasingly being talked about not only in diabetologists' offices, but also in the context of obesity treatment?

Ozempic (semaglutide) is a GLP-1 receptor agonist. This means it increases insulin secretion after a meal, inhibits glucagon, and slows stomach emptying—so it lowers blood sugar and curbs appetite. The result? Better glycemic control and gradual weight loss.

Mounjaro (tirzepatide) goes a step further. In addition to GLP-1, it also activates a second hormone – GIP – which translates into even stronger metabolic effects: more effective fat burning, a higher feeling of satiety and faster weight loss.

According to a study published in JAMA Internal Medicine , Mounjaro may be twice as effective as Ozempic in reducing weight. People taking tirzepatide were more likely to lose 10 to 15 percent of their body weight, making it an effective substance in treating obesity.

But Ozempic is not lagging behind – it gives very good results in many patients, especially if the treatment is combined with diet and physical activity.

The decision should be individual and based on the doctor's assessment. Ozempic may be better for people with high cardiovascular risk and drug tolerance problems. Mounjaro - for those who have larger weight loss goals and do not have financial constraints.

Both drugs can cause digestive problems: nausea, diarrhea, abdominal pain. In rare cases, more serious side effects, such as pancreatitis, can occur. Therefore, therapy should always be carried out under the supervision of a doctor.

It is not recommended to combine Ozempic and Mounjaro - it increases the risk of adverse reactions. It is possible to change one preparation for the other if it does not bring the expected results.

Ozempic is reimbursed for patients with type 2 diabetes who meet certain criteria (including BMI ≥30, HbA1c ≥7.5 percent). The cost of monthly therapy is about PLN 404. Mounjaro is not reimbursed, and the monthly expense is about PLN 1,080.

So if budget is a factor, Ozempic may be more affordable. However, it is also worth considering the potentially greater effectiveness of Mounjaro.